knowledge -WSS

knowledge

author：knowledge 2025-09-29 12:30:04 - browse：46

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Aspartame and sugar

WSS

In 'major milestone,' FDA approves first cell therapy for solid tumors

BMS, looking to build heart drug business, turns to AI for diagnosis

Surprise medical billing ban raises prices elsewhere

Biden administration begins canceling student loan debt for 804,000 borrowers

Secretariat’s lessons for human medicine

As AI regulations shape up, health tech startups beg for clarity

entertainment

knowledge

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Bird flu researchers hone in on Finland’s mink farms

Activists slam private health insurers over coverage restrictions

Hospitals are dialing back on venture capital investing

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Abridge raises $150m as clinical notes automation market heats up

Bright Health sells Medicare Advantage business to Molina

MD Anderson's Padmanee Sharma responds to research credit suit

Cancer drug shortages should be causing more outrage

Ukraine seeks to reclaim its role as a hub for clinical trials

focus

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Be careful with at

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Surprise medical billing ban raises prices elsewhere

Opioid cravings were reduced by anti

Judge sides with young activists in first

hotspot

Wikipedia

focus

leisure time